Clinical Response and Safety of Letrozole-based Therapy in Postmenopausal Sudanese Women with Estrogen Receptor-positive/HER2-Negative Breast Cancer: A Retrospective Cohort Study
Lina Hassan Elobied, Abdulbagi Elbadri Ali, Mohamed Thabit Ahmed, Kannan O. Ahmed, Yasir S. Kheir, Elmoiz Babekir & Bashir A. Yousef · Journal of Advances in Medical and Pharmaceutical Sciences · 2026
Introduction: Estrogen receptor-positive/HER2-negative breast cancer is the most common molecular subtype of breast cancer. Aromatase inhibitors such as letrozole are part of the standard endocrine treatment regimen for postmenopausal patients; however, real-world evidence on pat...
Open access
Research Article
10.9734/jamps/2026/v28i8883